Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings

Overview

Journal Antibodies (Basel)

Date 2019 Sep 25

PMID 31548530

Citations 7

Authors

Nina Moeker

Solveig Peters

Robert Rauchenberger

Nicolae Ghinea

Christian Kunz

Affiliations

Soon will be listed here.

Abstract

Background: The follicle-stimulating hormone (FSH)-receptor (FSHR) has been reported to be an attractive target for antibody therapy in human cancer. However, divergent immunohistochemical (IHC) findings have been reported for FSHR expression in tumor tissues, which could be due to the specificity of the antibodies used.

Methods: Three frequently used antibodies (sc-7798, sc-13935, and FSHR323) were validated for their suitability in an immunohistochemical study for FSHR expression in different tissues. As quality control, two potential therapeutic anti-hFSHR Ylanthia® antibodies (Y010913, Y010916) were used. The specificity criteria for selection of antibodies were binding to native hFSHR of different sources, and no binding to non-related proteins. The ability of antibodies to stain the paraffin-embedded Flp-In Chinese hamster ovary (CHO)/FSHR cells was tested after application of different epitope retrieval methods.

Results: From the five tested anti-hFSHR antibodies, only Y010913, Y010916, and FSHR323 showed specific binding to native, cell-presented hFSHR. Since Ylanthia® antibodies were selected to specifically recognize native FSHR, as required for a potential therapeutic antibody candidate, FSHR323 was the only antibody to detect the receptor in IHC/histochemical settings on transfected cells, and at markedly lower, physiological concentrations (ex., in Sertoli cells of human testes). The pattern of FSH323 staining noticed for ovarian, prostatic, and renal adenocarcinomas indicated that FSHR was expressed mainly in the peripheral tumor blood vessels.

Conclusion: Of all published IHC antibodies tested, only antibody FSHR323 proved suitable for target validation of hFSHR in an IHC setting for cancer. Our studies could not confirm the previously reported FSHR overexpression in ovarian and prostate cancer cells. Instead, specific overexpression in peripheral tumor blood vessels could be confirmed after thorough validation of the antibodies used.

Citing Articles

Follicle-stimulating hormone receptor expression in advanced atherosclerotic plaques.

Ghinea N, Liehn E, Grommes J, Delattre D, Olesen T Sci Rep. 2024; 14(1):10176.

PMID: 38702476 PMC: 11068877. DOI: 10.1038/s41598-024-60962-2.

Follicle-Stimulating Hormone Receptor Expression and Its Potential Application for Theranostics in Subtypes of Ovarian Tumors: A Systematic Review.

Bakker M, Brink G, Poot A, Braat A, Jonges G, Zweemer R Cancers (Basel). 2024; 16(6).

PMID: 38539473 PMC: 10969425. DOI: 10.3390/cancers16061140.

Inadequate detection of the FSHR complicates future research on extragonadal FSHR localization.

Tedjawirja V, Hooijer G, Dilara Savci-Heijink C, Kovac K, Balm R, de Waard V Front Endocrinol (Lausanne). 2023; 14:1095031.

PMID: 36875462 PMC: 9978812. DOI: 10.3389/fendo.2023.1095031.

Recent advances in understanding gonadotropin signaling.

Casarini L, Simoni M Fac Rev. 2021; 10:41.

PMID: 34046645 PMC: 8130412. DOI: 10.12703/r/10-41.

Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health.

Ghinea N Diseases. 2021; 9(2).

PMID: 33920299 PMC: 8167546. DOI: 10.3390/diseases9020028.

References

Ben-Josef E, Yang S, Ji T, Bidart J, Garde S, Chopra D . Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol. 1999; 161(3):970-6. View

Zheng W, Lu J, Luo F, Zheng Y, Feng Y, Felix J . Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol. 2000; 76(1):80-8. DOI: 10.1006/gyno.1999.5628. View

Plant T, Marshall G . The functional significance of FSH in spermatogenesis and the control of its secretion in male primates. Endocr Rev. 2001; 22(6):764-86. DOI: 10.1210/edrv.22.6.0446. View

Chu S, Rushdi S, Zumpe E, Mamers P, Healy D, Jobling T . FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Mol Hum Reprod. 2002; 8(5):426-33. DOI: 10.1093/molehr/8.5.426. View

Wang J, Lin L, Parkash V, Schwartz P, Lauchlan S, Zheng W . Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. Int J Cancer. 2002; 103(3):328-34. DOI: 10.1002/ijc.10848. View

Hai M, Lescop P, Loosfelt H, Ghinea N . Receptor-mediated transcytosis of follicle-stimulating hormone through the rat testicular microvasculature. Biol Cell. 2004; 96(2):133-44. DOI: 10.1016/j.biolcel.2003.11.008. View

Rzepka-Gorska I, Chudecka-Glaz A, Kosmowska B . FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary. Endocr Relat Cancer. 2004; 11(2):315-21. DOI: 10.1677/erc.0.0110315. View

Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E . Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol. 2006; 175(6):2072-7. DOI: 10.1016/S0022-5347(06)00273-4. View

Fritschy J . Is my antibody-staining specific? How to deal with pitfalls of immunohistochemistry. Eur J Neurosci. 2008; 28(12):2365-70. DOI: 10.1111/j.1460-9568.2008.06552.x. View

10.

Chen F, Oskay-Ozcelik G, Buhling K, Kopstein U, Mentze M, Lichtenegger W . Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer. Anticancer Res. 2009; 29(5):1575-8. View

11.

Nagayama Y, Wadsworth H, Chazenbalk G, Russo D, Seto P, Rapoport B . Thyrotropin-luteinizing hormone/chorionic gonadotropin receptor extracellular domain chimeras as probes for thyrotropin receptor function. Proc Natl Acad Sci U S A. 1991; 88(3):902-5. PMC: 50922. DOI: 10.1073/pnas.88.3.902. View

12.

Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A . Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010; 363(17):1621-30. DOI: 10.1056/NEJMoa1001283. View

13.

Sprengel R, Braun T, Nikolics K, Segaloff D, Seeburg P . The testicular receptor for follicle stimulating hormone: structure and functional expression of cloned cDNA. Mol Endocrinol. 1990; 4(4):525-30. DOI: 10.1210/mend-4-4-525. View

14.

Lenhard M, Lennerova T, Ditsch N, Kahlert S, Friese K, Mayr D . Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival. Histopathology. 2011; 58(6):990-4. DOI: 10.1111/j.1365-2559.2011.03848.x. View

15.

Siraj M, Pichon C, Radu A, Ghinea N . Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib. J Cell Mol Med. 2011; 16(9):2010-6. PMC: 3822971. DOI: 10.1111/j.1582-4934.2011.01495.x. View

16.

Xie Y, Wang H, Segaloff D . Extracellular domain of lutropin/choriogonadotropin receptor expressed in transfected cells binds choriogonadotropin with high affinity. J Biol Chem. 1990; 265(35):21411-4. View

17.

Mertens-Walker I, Baxter R, Marsh D . Gonadotropin signalling in epithelial ovarian cancer. Cancer Lett. 2012; 324(2):152-9. DOI: 10.1016/j.canlet.2012.05.017. View

18.

Sardella C, Russo D, Raggi F, Lombardi M, Urbani C, Brogioni S . Ectopic expression of FSH receptor isoforms in neoplastic but not in endothelial cells from pancreatic neuroendocrine tumors. J Endocrinol Invest. 2012; 36(3):174-9. DOI: 10.3275/8472. View

19.

Pawlikowski M, Pisarek H, Kubiak R, Jaranowska M, Stepien H . Immunohistochemical detection of FSH receptors in pituitary adenomas and adrenal tumors. Folia Histochem Cytobiol. 2012; 50(3):325-30. DOI: 10.5603/17850. View

20.

Frese K, Eisenmann M, Ostendorp R, Brocks B, Pabst S . An automated immunoassay for early specificity profiling of antibodies. MAbs. 2013; 5(2):279-87. PMC: 3893238. DOI: 10.4161/mabs.23539. View